The Government of India is engaging with the manufacturers of Amphotericin B to ramp up production of the drug domestically and also looking at increasing its imports. 

After reviewing the stock position with the manufacturers/importers, and studying the demand pattern of Amphotericin B, the Department of Pharma on 11th May, 2021 has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021. 

States have been requested to put in place a mechanism for equitable distribution of supplies amongst government and private hospitals and health care agencies. States have also been requested to publicise in the state the ‘Point of Contact’ for private and government hospitals to obtain the drug from this allocation. 

Further, states have been requested that judicious use may be made of the stock that has been already supplied as well as stock that has been allocated. The arrangements for supply will be monitored by the National Pharmaceuticals Pricing Authority (NPPA). 

A sudden increase in demand has been observed in some states for Amphotericin B which is being actively prescribed by the physicians to patients suffering from Mucormycosis, a post COVID complication.